Table 4 Adjusted comparison of acute respiratory-related hospitalisation in patients newly treated with antifibrotic drugs (multivariate analyses)
HR | 95% CI | p-value | |
|---|---|---|---|
Treatment | |||
Pirfenidone | 1.00 | – | – |
Nintedanib | 1.32 | 1.01–1.73 | 0.04 |
Age at treatment initiation | 0.99 | 0.98–1.01 | 0.41 |
Sex | |||
Male | 1.00 | – | – |
Female | 0.98 | 0.74–1.30 | 0.90 |
Year of antifibrotic treatment initiation | |||
2015 | 1.00 | – | – |
2016 | 0.70 | 0.53–0.91 | 0.01 |
Time from IPF diagnosis to treatment initiation | 1.01 | 1.00–1.01 | 0.02 |
Number of acute respiratory-related hospital admissions during the year prior to treatment initiation | |||
0 | 1.00 | – | – |
1 | 1.42 | 1.10–1.84 | 0.01 |
2 or more | 2.27 | 1.64–3.15 | < 0.01 |
Number of outpatient visits to a hospital physician during the year prior to treatment initiation | |||
0 | 1.00 | – | – |
1 or 2 | 1.08 | 0.68–1.72 | 0.75 |
3 or 4 | 0.99 | 0.61–1.60 | 0.97 |
5 or more | 1.11 | 0.69–1.78 | 0.66 |
Charlson comorbidity score | |||
1–2 | 1.00 | – | – |
3–4 | 1.33 | 0.91–1.94 | 0.14 |
5 or more | 1.35 | 0.87–2.09 | 0.18 |
Use of supplemental oxygen at baseline | |||
Yes | 2.02 | 1.57–2.60 | < 0.01 |